Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs' board, which met on February 9, 2026, has called an Extra-Ordinary General Meeting (EOGM) for March 16, 2026 to seek shareholder approval for three key items: (1) regularising the appointment of Mr. Shailendra Pathak as Whole Time Director, (2) appointing Mrs. Neha Sarda as an Independent Director, and (3) approving material Related Party Transactions with Aminova Infusions Pvt. Ltd., where Mr. Pathak holds a 50% equity stake. The board also approved the unaudited financial results for the quarter ended December 31, 2025, and noted the limited review report submitted by the statutory auditors. The signing authority is Chairman Sudhir Sethi.
Shareholders should watch the March 16 EOGM closely — approval of the related party deal with Aminova Infusions is notable because the incoming Whole Time Director has a direct 50% financial interest in that counterparty, raising a potential conflict-of-interest concern. Q3 results have been cleared but full numbers are not disclosed in this filing.